SecProbe.io

CORRESP
1
filename1.htm

    Giovanni Caruso

    Partner

    345 Park Avenue

    New York, NY 10154

    Direct     212.407.4866

Main       212.407.4000

Fax          212.407.4990

gcaruso@loeb.com

Via
EDGAR

January 13, 2025

Stacie
Gorman and Pam Howell

U.S. Securities & Exchange Commission

100 F Street, NE

Washington, D.C. 20549

Re: Stellar V Capital Corp. (Cayman Islands)

                                                                                Registration Statement on Form S-1

                                                                                Filed December 4, 2024

                                                                                File No. 333-283612

Dear
Ms. Gorman and Ms. Howell:

On
behalf of our client, Stellar V Capital Corp. (the “Company”), we hereby provide a response to the comments issued in a letter
dated December 24, 2024 (the “Staff’s Letter”) regarding the Company’s Registration Statement on Form S-1 (the
“S-1”). Contemporaneously, we are filing an Amendment No. 1 to the S-1 via EDGAR (the “Amendment No. 1”).

In
order to facilitate the review by the staff of the Securities and Exchange Commission (the “Staff”) of the Amended Registration
Statement, we have responded, on behalf of the Company, to the comments set forth in the Staff’s Letter on a point-by-point basis.
The numbered paragraphs set forth below respond to the Staff’s comments and correspond to the numbered paragraph in the Staff’s
Letter.

Registration
Statement on Form S-1

Cover
Page

1. We
note your revised disclosure regarding your ability to extend your completion window from 18 months to 21 months to complete an initial
business combination. We also note that your sponsor and affiliates are required to make a loan, within 10 days of the end of the
18-month period if the extension is elected and that the loan may be unrecoverable. Further, we note that you may be required to provide
additional loans if further extensions are voted on by the shareholders. It appears, from your revised disclosure, that your sponsor
and affiliates have, potentially, up to 40 days beyond the initial or any extended completion date to provide any required loan, given
the additional “30-day cure period” referenced in your revised disclosure. Please revise your Summary section, on page 1, to
define “due date” and “applicable deadline” as used regarding the 30-day cure period and extending the completion
window. Also clarify how the 30-day cure period works with any extensions of the completion window(s). Please clarify the impact if the
sponsor or affiliates ultimately do not provide the loans and how this affects the cure period. Finally, address how the 30-day
cure period and 10-day loan funding period are compatible with the requirement that shareholder funds be returned promptly if you do
not complete an initial business combination within the completion window. Additionally, we note on page 116, your disclosure still refers
to having 24 months to complete your initial business combination. Please revise to address this discrepancy.

Response: The Company revised the
disclosures on cover page, pages 1, 9, 53, 87, 105 and 116 to disclose that the completion window is 21 months without the 3-month
extension. The Company also revised the disclosures on cover page, pages 10, 25, 26, 45 and 105 to remove the 30-day cure period. In
addition, the Company corrected the disclosure on page 116 in accordance with the Staff’s comment.

    Los
    Angeles     New York     Chicago     Nashville     Washington,
    DC     San Francisco     Beijing     Hong Kong    www.loeb.com

    For
    the United States offices, a limited liability partnership including professional corporations. For Hong Kong office, a limited liability
    partnership.

    Stacie Gorman and Pam Howell

    January 13, 2025

Page 2

Summary

Summary
of Risk Factors, page 39

2. We
note that you removed summary risk factors that appear to make an investment in you or your offering speculative or risky. Specifically,
we note the risks related to the time to complete your business combination, the ability of management to purchase shares which could
impact the public float and the ability to complete the combination, the dilution impact on investors, and the competition among SPACs
for targets. Please revise to include these summary risks or advise us why they should not be addressed in the summary risk factor
section. Please refer to Item 105(b) of Regulation S-K.

Response: The Company revised the disclosures to
include the summary of the indicated risk factors on page 40.

Part
II. Information not Required in Prospectus

Item
16. Exhibits and Financial Statement Schedules., page II-2

3. We
note that assumption 2.10 in Exhibit 5.1, assumes the due authorization and execution of all documents. This assumption appears overly
broad as it relates to the company.  Please have counsel revise the opinion as appropriate to exclude the company from this assumption. Refer
to Section II.B.3.a of Staff Legal Bulletin No. 19.

Response: In response to the Staff’s comments,
a revised opinion has been filed as Exhibit 5.1.

    Stacie Gorman and Pam Howell

    January 13, 2025

Page 3

Please
call me at 212-407-4866 if you would like additional information with respect to any of the foregoing. Thank you.

    Sincerely,

    /s/ Giovanni Caruso

    Giovanni Caruso

    Partner

cc:
Prokopios Tsirigakis